The most common TLCD1 gene alterations were amplifications in bladder urothelial carcinoma, uterine corpus endometrial carcinoma, breast cancer and uterine carcinosarcoma, and mutations in esophageal adenocarcinoma, lung squamous cell carcinoma, gastric carcinoma, lung adenocarcinoma, and cutaneous melanoma (Figure 9A). This evidence concerns the gene TLCD1 and lung adenocarcinoma.